Cancer Immunology, Immunotherapy

, Volume 52, Issue 11, pp 661–662 | Cite as

Cellular immunity for cancer chemoimmunotherapy—an overview

Symposium in Writing
First Online:
Received:
Accepted:

Keywords

Anticancer Drug Immunomodulating Effect Lymphopenia Antitumor Immune Response Mouse Mammary Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP (2000) Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60:2444–2448PubMedGoogle Scholar
  2. 2.
    Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockage in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100:4712–4717CrossRefPubMedGoogle Scholar
  3. 3.
    Hanahan D (1985) Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315:115–122PubMedGoogle Scholar
  4. 4.
    Cao ZA, Daniel D, Hanahan D (2002) Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer 2:11CrossRefPubMedGoogle Scholar
  5. 5.
    Ganss R, Limmer A, Sacher T, Arnold B, Hammerling GJ (1999) Autoaggression and tumor rejection: it takes more than self-specific T-cell activation. Immunol Rev 169:263–272PubMedGoogle Scholar
  6. 6.
    Evans SS, Wang WC, Bain MD, Burd R, Ostberg JR, Repasky EA (2001) Fever-range hyperthermia dynamically regulates lymphocyte delivery to high endothelial venules. Blood 97:2727–2733CrossRefPubMedGoogle Scholar
  7. 7.
    Mihich E, Ehrke MJ (1991) Immunomodulation by anticancer drugs. In: Devita V, Hillman S, S. Rosenberg S (eds) Biologic therapy of cancer: principles and practice. Part III. Alternative strategies for biologic therapy. Lippincott, Philadelphia, pp 776–786Google Scholar
  8. 8.
    Ehrke MJ, Mihich E (1996) Immunopharmacology of anticancer agents. In: Hadden JW, Szentivanyi A (eds) Immunopharmacology reviews, vol 2. Plenum, New York, pp 103–127Google Scholar
  9. 9.
    Ujhazy P, Zaleskis G, Mihich E, Ehrke MJ, Berleth ES (2003) Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells. Cancer Immunol Immunother 52:463–472Google Scholar
  10. 10.
    Cowens JW, Ozer H, Ehrke MJ, Greco W, Colvin M, Mihich E (1984) Inhibition of the development of suppressor cells in culture by 4-Hydroperoxy-cyclophosphamide. J Immunol 132:95–100Google Scholar
  11. 11.
    Schiavoni G, Mattei F, Pucchio TD, Santini SM, Bracci L, Belardelli F, Proietti E (2000) Cyclophosphamide induced type I interferon and augments the number of CD44hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95:2024PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.Grace Cancer Drug Center, Rosswell Park Cancer InstituteNew York State Department of HealthBuffaloUSA

Personalised recommendations